Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596487 | 0.94 | KDM4E (0.54) | POLBCD274TSHRHTTMEN1 | |
| SCHEMBL3605190 | 0.91 | KMT2A (0.49) | POLBCD274TSHRHTTALDH1A1 | |
| SCHEMBL3602569 | 0.90 | KMT2A (0.48) | POLBCD274TSHRHTTALDH1A1 | |
| SCHEMBL3597719 | 0.90 | KMT2A (0.48) | POLBCD274TSHRHTTALDH1A1 | |
| SCHEMBL3608056 | 0.88 | GRIN2B (0.41) | POLBCD274TSHRHTTALDH1A1 | |
| SCHEMBL3604427 | 0.87 | GRIN2B (0.45) | POLBCD274HTTALDH1A1CYP3A4 | |
| SCHEMBL3601480 | 0.83 | GAA (0.49) | POLBALDH1A1CYP3A4CYP2C19KMT2A | |
| SCHEMBL3606199 | 0.83 | KMT2A (0.41) | POLBTSHRALDH1A1MEN1KMT2A | |
| SCHEMBL3608528 | 0.82 | MTNR1A (0.47) | POLBTSHRHTTALDH1A1MEN1 | |
| SCHEMBL13115710 | 0.81 | GRIN2B (0.45) | POLBTSHRALDH1A1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | POLB 4479/4885CD274 540/4885TSHR 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.